Pharmaceuticals

Sinobioway Medicine

Sinobioway Medicine released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 62.76 M, actual EPS CNY -0.072

Sinobioway Medicine released FY2025 Annual Earnings on April 28 After-Market (BJT), actual revenue CNY 274.81 M, actual EPS CNY -0.1763

Sinobioway Medicine released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 43.86 M, actual EPS CNY -0.0822

Sinobioway Medicine to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Sinobioway Medicine to Release FY2025 Earnings on April 29 After-Market (BJT)

Sinobioway Medicine released FY2025 9 Months Earnings on October 28 During-Market BJT, actual revenue CNY 212.05 M, actual EPS CNY -0.1042

Sinobioway Medicine released FY2025 Q3 earnings on October 28 During-Market BJT, actual revenue CNY 141.28 M, actual EPS CNY -0.0022

Sinobioway Medicine to Release FY2025 Q3 Earnings on October 29 During-Market BJT

Sinobioway Medicine released FY2025 Semi-Annual Earnings on August 19 Pre-Market (BJT), actual revenue CNY 70.77 M, actual EPS CNY -0.102

Sinobioway Medicine released FY2025 Q2 earnings on August 19 Pre-Market (BJT), actual revenue CNY 35.44 M, actual EPS CNY -0.0461

Sinobioway Medicine to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

ST Unimen Anticipates Loss for First Half of 2025

ST Unimen Imposes Other Risk Warning Due to Subsidiary Suspension of Production and Sales

Unimedic Pharmaceutical Repeats C Rating in ESG Assessment

Unmeng Medicine Stock Abnormal Fluctuation and Subsidiary Operational Troubles

Unimedicine's Subsidiary Tianjin Unimedicine Suspended from Production and Sales

Unimedic Pharmaceutical's Wholly-Owned Subsidiary Increases Investment in Gukang Pharmaceutical

Unimark MediDiscloses Progress on Subsidiary's Rectification

Tianjin FDA Suspends Production and Sales of Tianjin Unimedic

Unmeng Pharmaceutical Received Sinovac Biotech Dividend of 135 Million RMB

002581

The Intermediate People's Court of Zibo City made a second-instance judgment on the equity dispute case of Sinobioway Medicine, revoking the embezzlement charges against three defendants, with significant reductions in their sentences and fines. Pan Aihua was sentenced to five years for the crime of misappropriation of funds, Li Pengfei was sentenced to two years for the crime of forgery of official documents and one year for the crime of forgery of company seals, and Luo Deshun was sentenced to three years for the crime of misappropriation of funds. Pan Aihua is required to return 12.75 million yuan to Sinobioway Biomedicine Co., Ltd

Wallstreetcn

Sinobioway Medicine equity case second instance retrial: revocation of embezzlement charge, reduced prison term and fine

002007

In September, multiple provinces including Beijing and Zhejiang have successively launched this year's influenza vaccine vaccination work. A piece of news stating that "the unit price of the public-funded influenza vaccine has dropped to 5.5 yuan" has attracted industry attention. On September 1 and 2, the National Public Resources Trading Platform (Beijing) successively released the winning announcements for the 2025 Beijing influenza vaccine immunization and non-immunization procurement projects, with HUALAN BIOLOGICAL, Shanghai Institute of Biological Products, and Beijing Kexing being awarded the "immunization" project. (Yicai)

36Kr

HUALAN BIOLOGICAL

The flu vaccine has a "freezing point price" of 5.5 yuan

ST Sinobioway Medicine announced that in the first half of 2025, operating revenue was 70.7715 million yuan, a year-on-year decrease of 66.42%. The net loss attributable to shareholders of the listed company was 67.3027 million yuan, compared to a net loss of 29.6149 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital using reserves

Zhitong

Sinobioway Medicine: Net loss of 67.3027 million yuan in the first half of 2025

Beijing Kexing Holdings Co., Ltd. subsidiary Beijing Kexing Biological Products Co., Ltd. independently developed the combined hepatitis A and B vaccine Beirlaifu, which has obtained the drug re-registration approval notice, making it the only combined hepatitis A and B vaccine approved for market in China

Sinovac's combined hepatitis A and B vaccine, Beirlaifu, is re-registered for market launch

ST Sinobioway Medicine announced that its controlling subsidiary, Tianjin Sinobioway Biomedical Co., Ltd., has been subjected to risk control measures that suspend production and sales, and it is expected that normal production and business activities cannot be resumed within three months. This triggers relevant provisions of the "Shenzhen Stock Exchange Stock Listing Rules." Starting from July 8, 2025, it will be subject to other risk warnings, and the stock abbreviation will be changed to "ST Sinobioway." The daily price fluctuation limit for stock trading will be 5%

ST Sinobioway Medicine: Tianjin Sinobioway is subject to other risk warnings

Sinobioway Medicine's controlling subsidiary, Tianjin Sinobioway Biomedicine Co., Ltd., is expected to be unable to resume normal production. Starting from July 8, 2025, the stock will be subject to "other risk warnings," and its abbreviation will be changed to "ST Sinobioway." After a one-day suspension, it will resume trading with a daily price fluctuation limit reduced from 10% to 5%

Sinobioway Medicine has been subjected to other risk warnings, and its stock abbreviation has been changed to "ST Sinobioway"

301263

300436

603716

The innovative drug sector opened high again, with Thalys hitting a 4-day limit up, T&K and Zhongyuan Union opening 6% higher, and Cosunter, Sinobioway Medicine, and Changchun High-tech all opening higher

Cosunter

Thalys

The innovative drug sector opened high again, Thalys has achieved a 4-day consecutive limit up

Sinobioway Medicine announced that its holding subsidiary, Tianjin Sinobioway Biomedicine Co., Ltd., may trigger other risk warnings due to the suspension of production and sales. According to the relevant regulations of the Shenzhen Stock Exchange, if the company's production and operation are severely affected and it is expected to be unable to resume normal operations within three months, risk warnings will be implemented. This event has a significant impact on the production and operation of Sinobioway Medicine

Sinobioway Medicine: The company is at risk of triggering other risk warnings

300485

688520

688068

300181

Thalys has gained three consecutive trading limits, while Sinocelltech, Microchip Biotech, Science Sun Pharm, Changchun High-tech, and Sinobioway Medicine have all risen over 5%. Additionally, Huahai Pharmaceutical, Jolly, Hotgen, and others have followed suit. In terms of news, the National Healthcare Security Administration and the National Health Commission recently jointly issued "Several Measures to Support the High-Quality Development of Innovative Drugs," proposing 16 measures in 5 areas, emphasizing full-chain support for the research and development, market access, hospital use, and diversified payment of innovative drugs

Science Sun Pharm

Sinocelltech

Hotgen

Jolly

Chipscreen

huahaipharm

CCHT

Innovative drug concept stocks are repeatedly active, Thalys has three consecutive limit-ups

Sinobioway Medicine's wholly-owned subsidiary, Peking University Sinobioway (Shanghai) Biopharmaceutical Co., Ltd., plans to increase its investment in Sichuan Gukang Pharmaceutical by 45 million yuan to acquire a 51% stake. Gukang Pharmaceutical is a mature enterprise in traditional Chinese medicine materials and decoction pieces, with a stable market share and customer resources. This transaction will enhance Sinobioway Medicine's synergy and core competitiveness in the pharmaceutical field

Sinobioway Medicine's subsidiary plans to acquire a 51% stake in Traditional Chinese Medicine enterprise Gukan Pharmaceutical

Sinobioway Medicine(002581.SZ)